EUROPEAN HEALTH & PHARMACEUTICAL LAW REVIEW (EHPL)

The European Health & Pharmaceutical Law Review (EHPL) is the one-stop forum for analysis of health and pharmaceutical law and policy developments in the EU and its Member States. Offering an in-depth lead article, country and thematic reports, case notes and an overview of legal regulatory developments, the EHPL is a must read for both practitioners and academics.

Contributors to the journal report on key legislative developments in the EU and the Member States, and identify and analyse important judgments that shape the interpretation and application on of EU pharmaceutical law. For the issues of EHPL we welcome submissions of articles, country or policy reports and case annotations on, but not limited to, the following topics:

- pharmaceutical law and policy (regional, national, international);
- Commission decisions (EMA opinions) and regulatory guidelines;
- national EU, and International Jurisprudence;
- medical devices;
- borderline cases: pharmaceuticals/food/cosmetics/chemicals
- patents /trademarks
- health technology assessment and pricing/reimbursement
- digital health/big data

All contributions will be subject to double blind peer-review before acceptance for publication and are required to conform to the author guidelines available at: www.lexxion.eu/ehpl/#authors

We are accepting submissions on a rolling basis

Send submissions to:

Jakob McKernan
Executive Editor
mckernan@lexxion.eu
+49-30-81 45 06-10